AAHIVM Welcomes New Policy Director and Programs Manager to the Academy Team

AAHIVM Welcomes New Policy Director and Programs Manager to the Academy Team

Washington, DC: The American Academy of HIV Medicine (AAHIVM), the nation’s largest independent HIV provider organization, today announced the hire of Anna Forbes, MSS, as the organization’s new Director of Public Policy and Eryn Greaney as Programs and Policy Manager.

A seasoned professional with over thirty years in the public health sector, Ms. Forbes will oversee the AAHIVM policy department in its efforts to leverage the perspective and the powerful voices of HIV health care providers to influence health policy that affects HIV practitioners and the care they deliver.  Currently, AAHIVM advocates on both state and federal levels, with policymakers in all branches of government, to advise them on issues such as reimbursement, care and treatment access, the HIV workforce, prevention education and other policy items of concern to HIV providers.

Ms. Forbes comes to AAHIVM with deep experience in public education, policy analysis, and social mobilization around gender, human rights and HIV prevention needs. Most recently, she has worked on a number of international education campaign including SisterLove, Inc’s U.S. Women and PrEP Working Group and is currently completing her work with the Sero Project in which she is leading the development of a Network Empowerment Project Tool Kit.

An accomplished writer, Ms. Forbes has authored a variety of articles, case studies and reports including policy briefs for the International AIDS Vaccine Initiative on fast tracking an improved HIV/AIDS response for women and girls in Sub-Sahara Africa and also co-wrote The Business Case for Female Condoms for Global Health Visions which documented the economic and social benefits to countries heavily burdened by HIV. She has been published in a number of books, journals and anthologies throughout her career.

“We are confident that Anna will be a tremendous asset to our organization thanks to her extensive knowledge and impressive experience within the HIV/AIDS community,” stated James M. Friedman, executive director of AAHIVM. “With the current political challenges and ever-changing uncertainties facing the HIV advocacy community, we know the members of AAHIVM will be well represented on both the federal and state levels thanks to Anna’s leadership.”

Also joining the Academy team is Eryn Greaney, a health specialist with a track record of designing, implementing, and monitoring domestic and international projects. Ms. Greaney comes to AAHIVM from the United States Peace Corps where she served as a Health Extension Specialist in Nuaso, Ghana. In this capacity, Ms. Greaney developed and implemented health education programs on HIV/AIDS, including a three-month HIV/AIDS awareness program for junior high school students that focused on prevention, stigma reduction and gender equality. She also held an internship with AIDS United.

As the Programs and Policy Manager at AAHIVM, Ms. Greaney will be instrumental in organizing much of the Academy’s educational programmatic activities. AAHIVM’s educational and professional development programs help HIV care providers remain current with HIV’s rapidly evolving treatment landscape. Ms. Greaney will ensure members access a variety of CME/CE opportunities on both HIV and non-HIV topics through a diverse mix of educational vehicles including online courses, regional workshops and meetings, and educational materials.

“Eryn’s unique background and energy will be a great fit for our dynamic organization,” stated Friedman. “Both Eryn and Anna offer new experiences and perspectives that will help the Academy continue to grow, prosper and thrive.”

####

About AAHIVM

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioners and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed providers give direct care to the majority of HIV patients in the US.